Streetbeat News

Analyst Ratings

COST

Truist Securities analyst Scot Ciccarelli has maintained a 'Buy' rating on Costco Wholesale (NASDAQ:COST) and raised the price target from $597 to $619.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 3:45 pm

ASML

Analyst Ming-Chi Kuo suggests that ASML Holding is likely to cut its EUV equipment shipment forecasts for 2024 by about 20–30%. This is due to lower than expected demand from Apple and Qualcomm, lower demand for Samsung's 3GAP+ and Intel's 20A, and delayed memory expansion plans from Samsung, Micron, and SK Hynix. The semiconductor sector is expected to bottom out in 2H23, but this timeline may be pushed back to 1H24/2Q24.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 3:45 pm

MLKN

Craig-Hallum analyst Alex Fuhrman maintains a Hold rating on MillerKnoll (NASDAQ:MLKN) and raises the price target from $20 to $25.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 3:43 pm

LYFT

UBER

September trends show strong demand for Uber and Lyft in the U.S. mobility market, with prices rising due to high demand. Needham analyst Bernie McTernan reiterated a Buy rating for Uber with a $60 price target, while maintaining a Hold rating for Lyft. Uber's average prices have reached a two-year high, being 31% more expensive than Lyft. Despite Uber's higher prices, Lyft has not been able to gain a significant market share, suggesting structural issues or a longer path to competitive pricing.

Portfolio Pulse from Anusuya Lahiri

September 27, 2023 | 3:43 pm

MRK

MRNA

MYNZ

PFE

Pharmaceutical companies, including Pfizer Inc and Moderna Inc, are leveraging the potential of mRNA technology, which has shown significant promise in the fight against various diseases. Mainz Biomed N.V., a molecular genetics diagnostic company, has announced it will present results from its ColoFuture study that assessed the potential of mRNA biomarkers in colorectal cancer test screening. The company's trial results showed a sensitivity for colorectal cancer of 94% with a specificity of 97%. Mainz Biomed is also developing PancAlert, an early-stage pancreatic cancer screening test.

Portfolio Pulse from Upwallstreet

September 27, 2023 | 3:43 pm

SNX

RBC Capital analyst Ashish Sabadra has reiterated a 'Sector Perform' rating on TD Synnex (NYSE:SNX) and maintained a price target of $97.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 3:39 pm

NTNX

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on Nutanix (NASDAQ:NTNX) and raises the price target from $43 to $47.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 3:35 pm

EOG

JP Morgan analyst Arun Jayaram maintains an Overweight rating on EOG Resources and raises the price target from $145 to $156.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 3:32 pm

JNJ

A significant amount of unusual options activity has been observed for Johnson & Johnson (NYSE:JNJ), indicating a bullish stance by a large investor or institution. The sentiment among these big-money traders is split 60% bullish and 40% bearish. The targeted price range for JNJ over the last 3 months has been $135.0 to $175.0. The current price of JNJ is down -1.45% at $156.72. Analysts from Barclays, Cantor Fitzgerald, Wells Fargo, and Morgan Stanley have maintained their ratings on JNJ, with price targets ranging from $158 to $215.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 3:32 pm

ABNB

A significant number of investors have taken a bearish stance on Airbnb (NASDAQ:ABNB), with 80% of detected trades being bearish and 20% bullish. The trades include 6 puts amounting to $270,434 and 4 calls amounting to $145,788. Whales have been targeting a price range from $110.0 to $172.5 for Airbnb over the last 3 months. Truist Securities maintains a Hold rating on Airbnb with a price target of $126.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 3:31 pm